Biologic treatments for canine atopic dermatitis including monoclonal antibodies targeting IL-31 and IL-4/13 pathways have transformed management of this chronic, pruritic skin condition.
Biologics for canine atopy have transformed the welfare of affected dogs by targeting specific pruritic pathways rather than broadly suppressing immunity. Dogs that respond to biologic treatment achieve sustained itch relief that dramatically improves quality of life without the side effects of long-term steroid use. The welfare advance represented by targeted cytokine blockade is comparable to the revolution biologics produced in human dermatology.